Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
7.45
+0.80 (12.03%)
At close: Aug 17, 2026, 4:00 PM EDT
7.46
+0.01 (0.13%)
Pre-market: Aug 18, 2026, 8:45 AM EDT
Capricor Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
231
Market Cap
433.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.27M | -2.91M | -11.55% |
| Dec 31, 2023 | 25.18M | 22.63M | 886.81% |
| Dec 31, 2022 | 2.55M | 2.31M | 941.85% |
| Dec 31, 2021 | 244.90K | -65.35K | -21.06% |
| Dec 31, 2020 | 310.25K | -694.78K | -69.13% |
| Dec 31, 2019 | 1.01M | -666.33K | -39.87% |
| Dec 31, 2018 | 1.67M | -994.98K | -37.32% |
| Dec 31, 2017 | 2.67M | -1.33M | -33.32% |
| Dec 31, 2016 | 4.00M | -1.52M | -27.53% |
| Dec 31, 2015 | 5.52M | 730.95K | 15.27% |
| Dec 31, 2014 | 4.79M | 4.28M | 851.19% |
| Dec 31, 2013 | 503.23K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 1.35M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fennec Pharmaceuticals | 59.22M |
| Editas Medicine | 47.01M |
| X4 Pharmaceuticals | 15.85M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
| ProKidney | 818.00K |
| Inhibikase Therapeutics | 1.00 |
CAPR News
- 2 hours ago - CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop - PRNewsWire
- 21 hours ago - Kaplan Fox Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Act Before the Lead Plaintiff Deadline on September 28, 2026 - GlobeNewsWire
- 1 day ago - Capricor Therapeutics reports Q2 EPS (70c), consensus (58c) - TheFly
- 1 day ago - Capricor Therapeutics expects cash to fund operations for at least 12 months - TheFly
- 1 day ago - Capricor Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald - TheFly
- 1 day ago - Cantor upgrades Capricor on ‘major update’ from earnings call - TheFly
- 1 day ago - Capricor Therapeutics: FDA ‘willing’ to review BLA amendment, extend PDUFA date - TheFly
- 1 day ago - Capricor jumps 83% after FDA review update, Cantor upgrade - TheFly